Personal information

Websites & social links

LinkedIn
BlueSky
Mastodon
X

Activities

Collapse all

Employment (7)

Achilles Therapeutics: Stevenage, Hertfordshire, GB

2023-02-01 to present | Head of Translational Science Product Phenotyping (Research and Development)
Employment
Source: Self-asserted source
Miha Kosmac

Achilles Therapeutics: Stevenage, Hertfordshire, GB

2021-05-31 to present | Team Leader Product Characterisation (R&D)
Employment
Source: Self-asserted source
Miha Kosmac

Kymab Ltd: Cambridge, Cambridgeshire, GB

2018-07 to present | Senior Research Scientist (TA Immuno-oncology)
Employment
Source: Self-asserted source
Miha Kosmac

Kymab Ltd: Cambridge, Cambridgeshire, GB

2017-01 to present | Research Scientist II - Immuno-Oncology (Pharmacology and Translational Sciences)
Employment
Source: Self-asserted source
Miha Kosmac

Kymab Ltd: Cambridge, Cambridgeshire, GB

2015-09 to 2015-12 | Research Scientist II - Assay development and screening (Antibody Discovery)
Employment
Source: Self-asserted source
Miha Kosmac

Kymab Ltd: Cambridge, Cambridgeshire, GB

2012-10-02 to 2014-12 | Research Scientist - Molecular Biology (Antibody Discovery)
Employment
Source: Self-asserted source
Miha Kosmac

Blood Transfusion Centre of Slovenia: Ljubljana, SI

2011-05 to 2012-09 | Research and Development Associate
Employment
Source: Self-asserted source
Miha Kosmac

Education and qualifications (1)

University of Ljubljana: Ljubljana, SI

2006-10-01 to 2011-04-11 | PhD
Education
Source: Self-asserted source
Miha Kosmac

Works (19)

SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD

2017-09 | Other
Source: Self-asserted source
Miha Kosmac

Antibodies and immunocytokines

2017-04 | Other
Source: Self-asserted source
Miha Kosmac

Anti-hOX40L antibodies, uses, and methods

2017-03 | Other
Source: Self-asserted source
Miha Kosmac

Antibodies and immunocytokines

2017-02 | Other
Source: Self-asserted source
Miha Kosmac

Synergistic combinations of OX40L antibodies for the treatment of GVHD

2016-12 | Other
Source: Self-asserted source
Miha Kosmac

Synergistic combinations of ox40l antibodies for the treatment of gvhd

2016-10 | Other
Source: Self-asserted source
Miha Kosmac

Anti-human OX40L antibodies and methods of treating graft versus host disease with the same

2016-09 | Other
Source: Self-asserted source
Miha Kosmac

Anti-human OX40L antibodies

2016-01 | Other
Source: Self-asserted source
Miha Kosmac

Anti-human OX40L antibodies and methods of treatment

2015-09 | Other
Source: Self-asserted source
Miha Kosmac

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

Nature biotechnology
2014 | Journal article
Source: Self-asserted source
Miha Kosmac

THU0295 Isotype characterization of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab

Annals of the Rheumatic Diseases
2013 | Journal article
Source: Self-asserted source
Miha Kosmac

Anti-drug antibodies are associated with diminished drug levels and treatment failure

2012 | Journal article
Source: Self-asserted source
Miha Kosmac

ISOTYPE CHARACTERIZATION OF ANTI-INFLIXIMAB ANTIBODIES IN PEDIATRIC PATIENTS WITH RHEUMATIC DISEASES TREATED WITH INFLIXIMAB

ANNALS OF THE RHEUMATIC DISEASES
2012 | Conference paper
Source: Self-asserted source
Miha Kosmac

Vaccine development in prion diseases

Immunology
2012 | Journal article
Source: Self-asserted source
Miha Kosmac

Anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
2011 | Conference paper
Source: Self-asserted source
Miha Kosmac

Epitope mapping of a PrP (Sc)-specific monoclonal antibody: identification of a novel C-terminally truncated prion fragment

Molecular immunology
2011 | Journal article
Source: Self-asserted source
Miha Kosmac

Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab

Pediatric research
2011 | Journal article
Source: Self-asserted source
Miha Kosmac

Discrimination between prion-infected and normal brain with monoclonal antibodies specific for C-terminally truncated PrP fragment

Prion 2009
2009 | Conference paper
Source: Self-asserted source
Miha Kosmac

Antibody variable-region sequencing as a method for hybridoma cell-line authentication

Applied microbiology and biotechnology
2008 | Journal article
Source: Self-asserted source
Miha Kosmac
How many people are using ORCID?